Kite obtains new R&D facilities to develop cell therapies

| By | Cancer Drugs, Drug Development, Gilead Sciences, R&D
0
46

Kite, a Gilead Company, announced it has leased a new facility in the Netherlands to engineer cell therapies in Europe.

The new site in Hoofddorp (SEGRO Park Amsterdam Airport) will enable Kite to efficiently manufacture and deliver its cell therapies to people living with cancer in Europe and will provide more than 300 new jobs when fully operational in 2020.

The facility will engineer and produce innovative cell therapies, including axicabtagene ciloleucel, a Chimeric Antigen Receptor T cell (CAR T) therapy that is currently under review by the European Medicines Agency and which is approved in the United States as Yescarta.

In addition to the Netherlands facility, Kite has recently purchased a new building in Santa Monica (USA) from Astellas Pharma Inc. that will be used for cell therapy research, development and the expansion of clinical manufacturing capabilities, and has leased a facility in Gaithersburg, Maryland.

The Maryland site will support the work of a new Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to develop adoptive cell therapies targeting patient-specific tumor neoantigens. Neoantigens are mutations found on the surface of cancer cells that are unique to each person and tumor, offering the potential for more targeted antitumor activity.

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.

SOURCE: gilead
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.